Skip to main content

Clinical Research

Our patent-pending neuromodulation technology delivers low-dose, pulsed, alternating current stimulation (tACS) which, as a type of non-invasive brain stimulation, has been shown to induce neural plasticity and entrain neural oscillations. 

We have conducted multiple clinical trials, including a bipolar II depression study at Mount Sinai Beth Israel Hospital, a Parkinson's study at the University of Maryland, three pilot studies during the height of the pandemic, a pivotal depression trial in 2022 that will be used to obtain a CE Mark in Europe for the acute treatment of depression in women, and a real world evidence anxiety study with the Seattle Police Department. We are preparing to launch a new depression study to obtain FDA approval for the treatment of depression.

The results of our most recent depression study are being prepared for scientific journal publication. Below is a graph that summarizes the results of our bipolar II depression study, published in the Journal of Nervous and Mental Disease in 2015.

McClure D, Greenman SC, Koppolu SS, Varvara M, Yaseen ZS, Galynker II. A Pilot Study of Safety and Efficacy of Cranial Electrotherapy Stimulation in Treatment of Bipolar II Depression. J Nerv Ment Dis. 2015;203(11):827-835. doi:10.1097/NMD.0000000000000378

Back to top